Table 1.
Baseline demographics, biochemistry and cancer characteristics
| No. | % | Range | |
|---|---|---|---|
| Demographics | |||
| No. of patients | 154 | ||
| Age at docetaxel initiation, yrs | 69 | (44–87) | |
| Cancer characteristics at original diagnosis | |||
| Tx N0 M0 | 69 | 45 | |
| N1–2 or M1 | 71 | 46 | |
| Unknown TNM stage | 14 | 9 | |
| Gleason ≤6 | 68 | 44 | |
| Gleason 7 | 23 | 15 | |
| Gleason 8–10 | 63 | 41 | |
| PSA (μg/L) | 238 | (2–3672) | |
| Pre-chemotherapy biochemistry | |||
| Hemoglobin (mmol/L) | 127 | (73–178) | |
| Alkaline phosphatase (U/L) (normal <350 U/L) | 309 | (57–2975) | |
| LDH (U/L) (normal <150 U/L) | 127 | (108–9353) | |
| PSA (μg/L) | 298 | (1–3212) | |
Empty cells do not have any applicable data associated with them. Tx = tumour; N0 = no regional lymph node metastasis; M0 = no distant metastasis; N1 = metastasis with a single lymph node mass 2 cm or less in greatest dimension, or multiple lymph nodes 2 cm or less in greatest dimension; N2 = metastasis with a single lymph node mass larger than 2 cm, but no more than 5 cm in greatest dimension, or multiple lymph nodes no more than 5 cm in greatest dimension; M1 = distant metastasis; TNM = tumour, node, metastasis; PSA = prostate-specific antigen; LDH = lactate dehydrogenase.